Autophagy activators normalize aberrant Tau proteostasis and rescue synapses in human familial Alzheimer's disease iPSC-derived cortical organoids
Sergio R. LabraiD, Jadon CompheriD, Akhil PrabhavalkariD, Mireya Almaraz, Claudia Cedeño KwongiD, Christine BaaliD, Maria V. TalantovaiD, Nima Dolatabadi, Julian Piña‐Sanz, Yubo Wang, Leonard YooniD, Swagata GhatakiD, Zi GaoiD, Yuting ZhangiD, Dorit TrudleriD, Lynée A. MasseyiD, Wei Lin, Anthony BalistreriiD, Michael BulaiD, Nicholas J. SchorkiD, Tony S. MondalaiD, Steven Robert HeadiD, Jeffery W. KellyiD, Stuart A. LiptoniD
Abstract
Alzheimers disease (AD) is the most common form of dementia worldwide. Despite extensive progress, the cellular and molecular mechanisms of AD remain incompletely understood, partially due to inadequate disease models. To illuminate the earliest changes in hereditary (familial) Alzheimers disease, we developed an isogenic AD cerebrocortical organoid (CO) model. Our refined methodology produces COs containing excitatory and inhibitory neurons alongside glial cells, utilizing established isogenic wild-type and diseased human induced pluripotent stem cells (hiPSCs) carrying heterozygous familial AD mutations, namely PSEN1{Delta}E9/WT, PSEN1M146V/WT, or APPswe/WT. Our CO model reveals time-progressive accumulation of amyloid beta (A{beta}) species, loss of monomeric Tau, and accumulation of aggregated high-molecular-weight (HMW) phospho(p)-Tau species. This is accompanied by neuronal hyperexcitability, as observed in early human AD cases on electroencephalography (EEG), and synapse loss. Single-cell RNA-sequencing analyses reveal significant differences in molecular abnormalities in excitatory vs. inhibitory neurons, helping explain AD clinical phenotypes. Finally, we show that chronic dosing with autophagy activators, including a novel CNS-penetrant mTOR inhibitor-independent drug candidate, normalizes pathologic accumulation of A{beta} and HMW p-Tau, normalizes hyperexcitability, and rescues synaptic loss in COs. Collectively, our results demonstrate these COs are a useful human AD model suitable for assessing early features of familial AD etiology and for testing drug candidates that ameliorate or prevent molecular AD phenotypes. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=200 SRC="FIGDIR/small/661453v2_ufig1.gif" ALT="Figure 1"> View larger version (58K): org.highwire.dtl.DTLVardef@12ac9c6org.highwire.dtl.DTLVardef@24eceaorg.highwire.dtl.DTLVardef@3e3238org.highwire.dtl.DTLVardef@1530d1e_HPS_FORMAT_FIGEXP M_FIG C_FIG
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 8
- FWCI
- 36.57
- Field percentile
- top 1%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Patient-Derived PSEN1 Cerebral Organoids Revealed Parallel Development of Amyloid-β Accumulation and Network Dysfunction
Andrijana Angelovski, Hana Hříbková, … Markéta Bébarová·Cellular and Molecular NeurobiologyPeer-reviewed·Jul 20, 2026
- Isogenic cortical organoids enable precision targeting of APP variant-specific pathways in Alzheimer's disease
Tobias Graß, Ilyas Mehmet Cosacak, … Natalia Rodríguez‐Muela·bioRxiv·Feb 20, 2026
- Enhanced Neuronal Activity and Asynchronous Calcium Transients Revealed in a 3D Organoid Model of Alzheimers Disease
Juan Yin, Antonius M.J. VanDongen·ACS Biomaterials Science & EngineeringPeer-reviewed·Dec 21, 2020
- TNFα-driven Aβ aggregation, synaptic dysfunction and hypermetabolism in human iPSC-derived cortical neurons
Alicia González Díaz, Elisa Belli, … Michele Vendruscolo·bioRxiv·Aug 30, 2024
- A scalable human neuron model of Alzheimer's disease relevant tauopathy reveals mechanisms linking Tau fibrillization to synaptic dysfunction
Joanna Lipka, Xiwei Shan, … Jasvinder K. Atwal·bioRxiv·Sep 12, 2026
- Presenilin-dependent regulation of tau pathology via the autophagy/proteasome pathway
Anna del Ser‐Badia, Carlos M. Soto-Faguás, … Carlos A. Saura·bioRxiv·Dec 21, 2023